André Luis Barreira

ORCID: 0000-0002-0989-2629
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Dialysis and Renal Disease Management
  • Adenosine and Purinergic Signaling
  • Global Maternal and Child Health
  • Renal and Vascular Pathologies
  • Healthcare Systems and Reforms
  • Antioxidant Activity and Oxidative Stress
  • Chronic Kidney Disease and Diabetes
  • Global Health Care Issues
  • Tissue Engineering and Regenerative Medicine
  • Renal and related cancers
  • Advanced Glycation End Products research
  • Pregnancy and Medication Impact
  • Dermatology and Skin Diseases
  • Atherosclerosis and Cardiovascular Diseases
  • Urological Disorders and Treatments
  • Network Security and Intrusion Detection
  • Connective tissue disorders research
  • Seaweed-derived Bioactive Compounds
  • Mesenchymal stem cell research
  • Central Venous Catheters and Hemodialysis
  • Healthcare Policy and Management
  • Software-Defined Networks and 5G
  • Proteoglycans and glycosaminoglycans research
  • Coenzyme Q10 studies and effects
  • Health Systems, Economic Evaluations, Quality of Life

Hospital Universitário Clementino Fraga Filho
2007-2024

Universidade Federal do Rio de Janeiro
2007-2024

Background. Oxidative stress is a significant contributor to cardiovascular diseases (CVD) in haemodialysis (HD) patients, predisposing the generation of oxidized low-density lipoprotein (oxLDL) or electronegatively charged LDL subfraction. Antioxidant therapy such as α-tocopherol acts scavenger lipid peroxyl radicals attenuating oxidative stress, which decreases formation oxLDL. The present study was designed investigate influence supplementation on concentration electronegative [LDL(−)],...

10.1093/ndt/gfn760 article EN Nephrology Dialysis Transplantation 2009-01-28

<i>Background:</i> Oxidative modification of low-density lipoprotein (LDL) has been demonstrated in patients with end-stage renal disease, where it is associated oxidative stress and plays a key role the pathogenesis atherosclerosis. In this context, generation minimally oxidized LDL, also called electronegative LDL [LDL(–)], active detectable sign atherogenic tendencies. The purpose study was to evaluate serum LDL(–) levels anti-LDL(–) IgG autoantibodies disease on dialysis,...

10.1159/000127982 article EN Nephron Clinical Practice 2008-04-24

Abstract Background Previous study showed that purinergic P2X7 receptors (P2X7R) reach the highest expression in first week after unilateral ureteral obstruction (UUO) mice, and are involved process of inflammation, apoptosis fibrosis renal tissue. We, herein, document role activation on third day UUO, as assessed by means BBG its selective inhibitor. Methods We investigated effects brilliant blue G (BBG), a P2X7R antagonist, kidney tissue response to UUO rats. For this purpose, male Wistar...

10.1186/s12882-020-01861-2 article EN cc-by BMC Nephrology 2020-05-29

The growing number of patients suffering from chronic renal disease is a challenge for the development innovative therapies. Benefits cell therapy in acute diseases animal models have been reported but seldom lesions. We present evidence improvement morphology model tubulointerstitial fibrosis. Wistar rats were submitted to unilateral ureteral obstruction (UUO), treated with bone-marrow mononuclear cells (UUO+BMMC) infused via cava vein, and killed on day 14. Labeled BMMC seen tissue after 7...

10.1159/000257514 article EN Cellular Physiology and Biochemistry 2009-01-01

The treatment of peritoneal dialysis (PD)-related peritonitis has been a matter extensive investigation, frequently generating therapeutic trials. Several combinations antibiotics have served as newer protocols and tended to be efficacious, comfortable, cost-effective. According the more recent recommendations from International Society for Peritoneal Dialysis, rationale empirical initial therapy clinically detected in PD patients follow bacterial profile derived cultured specimens...

10.1177/089686080702700113 article EN Peritoneal Dialysis International 2007-01-01

Background Heparanase-1 activation, albuminuria, and a decrease in glomerular heparan sulfate (HS) have been described diabetic nephropathy (DN). Glycosaminoglycan (GAG)-based drugs shown to renoprotective effects this setting, although recent trials questioned their clinical effectiveness. Here, we describe the of fucosylated chondroitin (FCS), novel GAG extracted from marine echinoderm, experimentally induced DN compared widely used GAG, enoxaparin (ENX). Methods Diabetes mellitus (DM) was...

10.1371/journal.pone.0106929 article EN cc-by PLoS ONE 2014-09-05

Diabetic nephropathy is one of the main causes end-stage renal disease. The present study investigated effect mononuclear cell (MC) therapy in rats subjected to diabetic nephropathy.Male Wistar were divided into control (CTRL), (DM), CTRL+MC and DM+MC groups. Diabetes was induced by a single injection streptozotocin (45 mg/kg, i.p.) and, 4 weeks later, 2×10(7) MCs injected via jugular vein.The DM groups showed increased glycemia, glomerular filtration rate tuff area versus normalized group....

10.1159/000354473 article EN cc-by-nc Cellular Physiology and Biochemistry 2013-01-01

Patients with focal segmental glomerulosclerosis (FSGS) who are refractory to drug treatment may present progressive loss of kidney function, leading chronic disease stage 5 under dialysis treatment. The safety systemic administration bone marrow-derived mononuclear cells (BMDMCs) has been shown in different preclinical models diseases. However, date, no study evaluated the and biodistribution BMDMCs after infusion renal arteries patients FSGS. We used a prospective, non-randomized,...

10.1155/2024/2385568 article EN cc-by Stem Cells International 2024-01-01

Chronic kidney disease (CKD) is defined based on structural or functional abnormalities of the kidneys, a glomerular filtration rate (GFR) below threshold 60 ml/min per 1.73 m 2 for more than 3 months. It an important noncommunicable with rising worldwide, becoming global public health problem. There are few studies about this problem, especially in low- and middle-income countries (LMIC), including Brazil, upper-middle-income country. The objective study was to determine cause-specific...

10.1371/journal.pgph.0002304 article EN cc-by PLOS Global Public Health 2024-01-24

You have accessJournal of UrologyInfections/Inflammation the Genitourinary Tract: Kidney & Bladder (II)1 Apr 20131149 BRILLIANT BLUE G, A P2X7 ANTAGONIST, ATTENUATES RENAL INFLAMMATION AND FIBROSIS IN UNILATERAL URETERAL OBSTRUCTION RATS José Monteiro Sad Pereira, André Luis Barreira, Alberto Schanaider, Christina Maeda Takiya, Maurilo Leite, and Carlos Miranda PereiraJosé Pereira Rio de Janeiro, Brazil More articles by this author , BarreiraAndré Barreira SchanaiderAlberto Schanaider...

10.1016/j.juro.2013.02.784 article EN The Journal of Urology 2013-03-27

Chronic kidney disease (CKD) is an important noncommunicable with a rising worldwide, becoming global public health problem. There are few studies about this problem, especially in low- and middle-income countries (LMIC), including Brazil.We calculated the crude mortality rates (CMR) for pediatric CKD patients from zero to 19 years old, based on ICD-10 causes of death diagnostic codes Global Burden Diseases Injuries Risk Factors Study’s (GBD) list data DATASUS 1996 2017. The average annual...

10.2139/ssrn.4375618 preprint EN 2023-01-01

Abstract Background Previous study showed that purinergic P2X7 receptors (P2X7R) reach the highest expression in first week after unilateral ureteral obstruction (UUO) mice, and are involved process of inflammation, apoptosis fibrosis renal tissue. We, herein, document role activation on third day UUO, as assessed by means BBG its selective inhibitor.Methods We investigated effects brilliant blue G (BBG), a P2X7R antagonist, kidney tissue response to UUO rats. For this purpose, male Wistar...

10.21203/rs.2.16699/v1 preprint EN cc-by Research Square (Research Square) 2019-11-01
Coming Soon ...